[Adjuvant tamoxifen duration: more large-scale randomized evidence is needed]
The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) overview of worldwide evidence has demonstrated that a few years of adjuvant tamoxifen produces a moderate but definite benefit in long-term survival. However, there is major uncertainty regarding the optimal duration of tamoxifen...
| Main Authors: | , , |
|---|---|
| Format: | Journal article |
| Language: | Japanese |
| Published: |
1997
|